---
name: CMIC HOLDINGS Co., Ltd.
slug: cmicgroup
site: both
website_domain: cmicgroup.com
summary: CMIC HOLDINGS is a Japanese healthcare group whose Pharmaceutical Solutions cover consulting, non-clinical CRO, CRO, CDMO, SMO and CSO services. The group says it supports pharmaceutical companies across the value chain from non-clinical stages through post-marketing.
tagline: 世界中の誰もがより健康で その人らしい生活を送るため、ヘルスケアの革新に貢献します
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: 
tier2_domain_verified: false
updated_at: 2026-11-03T00:03:01.632Z
services_count: 11
modalities_count: 0
indications_count: 0
locations_count: 0
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# CMIC HOLDINGS Co., Ltd.

世界中の誰もがより健康で その人らしい生活を送るため、ヘルスケアの革新に貢献します

Listed on cdmo.directory.

## Summary

CMIC HOLDINGS is a Japanese healthcare group whose Pharmaceutical Solutions cover consulting, non-clinical CRO, CRO, CDMO, SMO and CSO services. The group says it supports pharmaceutical companies across the value chain from non-clinical stages through post-marketing.

## Services

- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Clinical Operations
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Clinical Trial Services

## Long description

## Overview

CMIC Group (シミックグループ) presents itself as a healthcare group that aims to contribute to healthcare innovation. Its corporate site describes three solution areas: Pharmaceutical Solutions, Healthcare Solutions and Specialized Solutions.

## Pharmaceutical Solutions

- Consulting, Non-Clinical CRO, CRO, CDMO, SMO and CSO services.
- Positioned as an end-to-end solution covering the pharmaceutical value chain from non-clinical development through post-marketing.

## Healthcare and specialized solutions

- **Healthcare Solutions:** digital health and municipal support solutions.
- **Specialized Solutions:** solutions tailored to the needs of patients and medical institutions.

## Recent activity noted on the site

- Named a finalist in the Scrip Awards 2026 "Best CRO - Specialist Providers" category.
- Announced a joint venture, TriNebula Cell Tech, with Dai Nippon Printing and NEXEL, focused on global deployment of animal-alternative evaluation products.

## Related companies

- [Viralgen](/companies/viralgen) (Regulatory Affairs, US FDA Regulatory Strategy) — [Compare](/compare/cmicgroup/viralgen)
- [Altasciences](/companies/altasciences) (Phase I Clinical Trials, Phase II Clinical Trials) — [Compare](/compare/altasciences/cmicgroup)
- [Pharmaron](/companies/pharmaron) (Phase I Clinical Trials, Phase II Clinical Trials) — [Compare](/compare/cmicgroup/pharmaron)
- [Syngene International](/companies/syngeneintl) (Phase I Clinical Trials, Phase II Clinical Trials) — [Compare](/compare/cmicgroup/syngeneintl)
- [uBriGene](/companies/ubrigene) (US FDA Regulatory Strategy, EU EMA Regulatory Strategy) — [Compare](/compare/cmicgroup/ubrigene)
- [Nuvisan](/companies/nuvisan) (Phase I Clinical Trials, Phase II Clinical Trials) — [Compare](/compare/cmicgroup/nuvisan)
- [ResolveMass Laboratories Inc.](/companies/resolvemass) (Regulatory Affairs, US FDA Regulatory Strategy) — [Compare](/compare/cmicgroup/resolvemass)
- [Rotop Pharmaka GmbH](/companies/rotop-pharmaka) (US FDA Regulatory Strategy, EU EMA Regulatory Strategy) — [Compare](/compare/cmicgroup/rotop-pharmaka)

_Profile last updated: 2026-11-03T00:03:01.632Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.